A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 113 participants.

Also called NCT05975905

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 113 participants (enrolled count) (from the registry)
Sponsor
Keros Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT05975905
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Brazil, France, Germany, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05975905. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-17 (actual); primary completion 2025-03-05 (actual). Results posted on 2026-07-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Condition
Pulmonary Arterial Hypertension
Intervention (Biological)
Dose A KER-012
Intervention (Biological)
Dose B KER-012
Intervention (Biological)
Dose C KER-012
Intervention (Biological)
Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
Lead sponsor
Keros Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05975905
Content hash
73862684713982d758267d3d1083c844ec3115e4293b263e12bd4e051c7dd545